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ORIGINAL ARTICLE
Melphalan and dexamethasone with or without bortezomib in
newly diagnosed AL amyloidosis: a matched case–control
study on 174 patients
G Palladini1,2, P Milani1,2,3, A Foli1,2, M Vidus Rosin1,2, M Basset1,2, F Lavatelli1, M Nuvolone1,2, L Obici1,2, S Perlini3 and G Merlini1,2
Oral melphalan and dexamethasone (MDex) is a standard treatment for patients with AL amyloidosis who are not eligible for stem
cell transplantation at many referral centers. However, following encouraging reports on the activity of bortezomib combined with
alkylators and dexamethasone, these combinations are being moved to frontline therapy. We compared the outcome of 87 patients
treated with bortezomib plus MDex (BMDex) with that of 87 controls treated with MDex. Patients and controls were matched for
age, cardiac and renal function and free light chain burden. A higher rate of complete responses was observed with BMDex (42 vs
19%), but this did not result in a survival improvement in the overall population. However, a signiﬁcant survival advantage for
BMDex was observed in patients without severe (New York Heart Association class III or IV) heart failure and with N-terminal pro-
natriuretic peptide type-B o8500 ng/l. Patients treated with full-dose dexamethasone had similar response rates and survival
whether they received bortezomib or not. Intermediate-risk patients who are not ﬁt enough to receive high-dose dexamethasone
are likely to take the greatest advantage from the addition of bortezomib to MDex.
Leukemia advance online publication, 19 August 2014; doi:10.1038/leu.2014.227
INTRODUCTION
Immunoglobulin light chain (AL) amyloidosis is caused by a
plasma cell clone, which is usually of a modest size, producing a
light chain that misfolds and aggregates in the form of amyloid
ﬁbrils, causing systemic proteotoxicity.1 The natural history of this
disease is primarily determined by the severity of cardiac
dysfunction.2 Patients who present with advanced heart involve-
ment, deﬁned by very high levels of the cardiac biomarker
N-terminal pro-natriuretic peptide type-B (NT-proBNP), survive
only a few months and represent the most difﬁcult challenge for
treating physicians.3 Clinical and experimental evidence indicate
that cardiac damage in AL amyloidosis is mainly determined by a
direct toxicity exerted by the circulating amyloidogenic free light
chain (FLC).4–8 Thus, therapy of AL amyloidosis is aimed at
obtaining a rapid and profound FLC reduction by targeting the
amyloidogenic plasma cell clone with chemotherapy, while
attentively supporting involved organ function. Treatment
approaches are derived from multiple myeloma and are adapted
to the fragile amyloid patients, and novel agents are ﬁnding their
place in the therapeutic armamentarium for AL amyloidosis.9,10
Bortezomib is now a mainstay in the treatment of multiple
myeloma.11 Treatment approaches based on proteasome inhibi-
tion are expected to be highly efﬁcacious in AL amyloidosis,
because amyloidogenic plasma cells rely on proteasome activity
to deal with the proteotoxic stress caused by the misfolded light
chain.12–14 Two early series showed promising activity of
bortezomib in AL amyloidosis, emphasizing its rapid action.15,16
A prospective phase I/II clinical trial of bortezomib as a single
agent showed a hematologic response in approximately two
thirds of relapsed/refractory patients with AL amyloidosis.17,18
In this trial, tolerability in patients with cardiac involvement was
good, but subjects with advanced disease were excluded.19
A large retrospective study including 94 patients, most of whom
were relapsed or refractory after previous treatment, conﬁrmed
the efﬁcacy of this drug in combination with dexamethasone
(overall hematologic response rate 71%).20 Moreover, bortezomib
and dexamethasone can be used as ‘adjuvant treatment’ after
autologous stem cell transplant (ASCT), improving the quality of
response in almost 90% of cases who do not achieve complete
response (CR) after transplantation.21 More recently, high CR rates
(42–71%) were reported in two small independent series of
patients treated with the combination of cyclophosphamide,
bortezomib and dexamethasone.22,23 These encouraging results
led to the perception that bortezomib-based treatment is superior
to standard approaches for the treatment of AL amyloidosis, and
this drug is increasingly prescribed outside the framework of
clinical trials.
At our center, melphalan and dexamethasone (MDex)24–26 was
standard treatment for intermediate- and high-risk patients since
2004, whereas patients eligible for ASCT and those who have
potentially reversible contraindications to ASCT are transplanted
or treated with stem cell-sparing regimens.27 The safety and
efﬁcacy proﬁle of MDex in AL amyloidosis has been assessed in a
randomized clinical trial and in several, independent series. The
French multicenter trial showed no difference in response rate
and survival between MDex and risk-adapted ASCT.28 Despite the
general good tolerability of MDex, the toxicity of high-dose
dexamethasone in AL amyloidosis is not negligible, most common
concerns being ﬂuid retention and arrhythmias,29,30 requiring
dose reductions. Recently, we reported the results of a large
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retrospective study showing that hematologic response could be
achieved in 76% (CR in 31%) of patients who were ﬁt enough to
receive MDex with full-dose dexamethasone, whereas only 51%
(CR 12%) of patients responded to MDex with attenuated
dexamethasone.26 Other studies showed that MDex cannot
overcome the poor prognosis of patients with severe cardiac
involvement.31 Based on the early reports of efﬁcacy of
bortezomib combined with alkylators and bortezomib, starting
in 2007, we offered treatment with bortezomib associated with
MDex (BMDex) to all the patients who had access to the drug and
gave consent.
Currently, there is no study comparing novel agents combina-
tions with standard approaches in AL amyloidosis, and the results
of uncontrolled studies should be considered with great caution,
because the outcome can be very diverse depending on different
proportion of patients with advanced disease.32,33 In 2011, a
randomized clinical trial comparing MDex with BMDex was
initiated (NCT01277016), which is still ongoing in Europe and
Australia. However, the results of this trial will not be available for
at least 2 years, although the increasing use of bortezomib
combinations in routine clinical practice urgently requires some
indications on the most appropriate setting to employ this drug in
AL amyloidosis. Thus, we designed the present retrospective
matched case–control study to assess whether the addition of
bortezomib to MDex resulted in improved hematologic response
rate and overall survival in 174 patients with AL amyloidosis.
PATIENTS AND METHODS
The whole study population comprises 174 matched patients with AL
amyloidosis evaluated at our center between 2005 and 2012. The BMDex
cohort is composed of all the 87 consecutive subjects treated with this
regimen between 2007 and 2012. Bortezomib was added to standard
MDex in all the patients who gave consent and to whom the drug could be
prescribed according to Italian regulations. They were matched with 87
controls selected from a total of 335 subjects treated with MDex between
2005 and 2012. All the patients were newly diagnosed. The patients gave
written informed consent as approved by institutional Ethics Committee.
The amyloid deposits were characterized as AL-type by immunoelectron
microscopy or proteomics in all cases.34,35 Evidence of a monoclonal
component of the same isotype of that identiﬁed in the amyloid ﬁbrils at
serum and urine immunoﬁxation electrophoresis and/or an abnormal FLC
κ/λ ratio was required.36 Subjects with lytic bone lesions were excluded.
The patients were matched for age (5-year periods), presence of heart
and renal involvement, Mayo Clinic cardiac stage,37 NT-proBNP above or
below 8500 ng/l (a marker of advanced cardiac involvement),3 systolic
blood pressure above or below 100mmHg,3 treatment with full-dose (that
is, 40 mg on days 1–4) dexamethasone,26 estimated glomerular ﬁltration
rate above or below 30ml/min per 1.73m2 and difference between
involved (amyloidogenic) and uninvolved free light chain (dFLC) above or
below 180mg/l (this threshold having been recently incorporated in the
revised Mayo Clinic staging system).38 When more than one matched
control was available, we chose the one whose date of diagnosis was
closest to that of the BMDex patient.
All the patients started treatment within 1 month from diagnosis. All the
patients received oral melphalan (0.22mg/kg) and dexamethasone
(40mg/day) on days 1–4 in 28-day cycles. Bortezomib was added at the
dosage of 1.3 mg/m2 on days 1, 4, 8, and 11 in the BMDex cohort, and
was administered intravenously. Patients with repetitive ventricular
arrhythmias39 and/or ﬂuid retention 43% of body weight (referring to
usual non-edematous body weight)40,41 received attenuated MDex, with
dexamethasone 20mg/day.26 Melphalan was reduced by 25% in patients
with eGFR o30ml/min per 1.73m2 (six subjects in both cohorts). The
maximum allowed number of cycles was nine. Treatment was discon-
tinued in case of toxicity, in the event a CR or any hematologic response
plus organ response was obtained after cycle 6 or in case hematologic
response was not reached by cycle 3. Patients who did not achieve at least
partial response by cycle 3 were shifted to second-line therapy, as well as
those who obtained unsatisfactory responses after cycle 6.
Hematologic response was assessed 6 months after treatment initiation
according to the new consensus criteria of the International Society of
Amyloidosis.42 The analysis of response was by intent-to-treat, and the
patients who died before the evaluation of response were considered non-
responders. As organ responses can be delayed, we evaluated the best
organ response obtained before shifting to second-line therapy.
Toxicity was assessed monthly until completion of treatment and
graded according to the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.03 (National Institutes of Health, Bethesda, MD, USA). As
the criteria of organ (other than heart) progression and hematologic
progression have not been updated since 2005, and considering that in AL
amyloidosis organ dysfunction (particularly kidney damage) can progress
despite hematologic response, we calculated and analyzed time to next
therapy or death.26,43
Differences in variables between subgroups were evaluated by the
Mann–Whitney of χ2 tests, as appropriate. Survival curves were plotted
according to Kaplan–Meier and differences in survival were evaluated for
statistical signiﬁcance with the log-rank test. Survival was calculated from
the time of diagnosis. Moreover, a 6-month landmark analysis of survival
was performed to exclude patients who died early and could have
irreversible organ damage at diagnosis. MedCalc Statistical Software
version 13.0.6 (MedCalc Software bvba, Ostend, Belgium) was used for
computation.
RESULTS
A total of 87 patients treated with BMDex were matched with 87
controls who received MDex. The patients’ characteristics are
reported in Table 1. The only signiﬁcant difference between the
two cohorts was a higher proportion of patients with peripheral
neuropathy in the MDex group (19 vs 6%). This was expected
because patients with severe or painful neuropathy did not
receive bortezomib owing to its potential neurotoxicity. There was
no difference in the number of cycles performed in the two
cohorts.
Fifteen patients (17%) experienced grade 3–4 adverse events in
the MDex cohort and 19 (22%) in the BMDex cohort (P= 0.444).
Fluid retention and cytopenia were observed in 8 (9%) and 6 (7%)
patients in each cohort. Peripheral neuropathy was observed in 4
(5%) BMDex patients and in none of the subjects who received
MDex alone (P= 0.042). One patient in the BMDex cohort
developed renal failure during treatment and a deep venous
thrombosis occurred in one MDex patient.
Response was assessed according to the revised criteria of the
International Society of Amyloidosis.42 Complete response
required negative serum and urine immunoﬁxation and normal
FLC ratio, very good partial response was deﬁned as a dFLC
o40mg/l, and partial response required a decrease of dFLC
450%. Cardiac response or progression required a decrease or
increase in N-terminal natriuretic peptide type-B (NT-proBNP)
430% and 4300 ng/l. Baseline NT-proBNP had to be 4650 ng/l
to be evaluable. Renal response required a 450% decrease in
proteinuria in the absence of a ⩾ 25% reduction in eGFR plus a
⩾ 0.5 mg/dl increase in serum creatinine.44 Response to treatment
is reported in Table 2. A higher proportion of CRs was observed in
the BMDex cohort (42 vs 19%), and this resulted in a higher overall
hematologic response rate (69 vs 51%). Importantly, when the
analysis was restricted to the 23 patients treated with full-dose
dexamethasone in each cohort, there was no signiﬁcant difference
in hematologic response rate (Table 2). The time to hematologic
response could be calculated in 15 subjects, 6 receiving MDex and
9 receiving BMDex, who had monthly assessments of dFLC. All of
them received full-dose dexamethasone. Median time to ﬁrst
response was 1.4 months (range 0.9–2.7 months) in the MDex
group and 1.1 months (range 0.9–2.3 months) in the BMDex
group. A cardiac response was achieved in 10 (13%) and 12 (16%)
in the MDex and BMDex patients, respectively (P= 0.644). A renal
response was observed in 15 (27%) subjects in the MDex cohort
and in 9 (16%) patients in the BMDex group (P= 0.166). In the
overall study population, the median time to cardiac response was
5.5 months (range 1.6–7.7 months) and median time to renal
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response was 8.2 months (range 3.9–18.6 months) with no
signiﬁcant differences between the two cohorts.
The median follow-up of living patients was 26 months. Forty-
eight patients (55%) died in the MDex cohort and 34 (39%) in the
BMDex cohort. The proportion of patients dying in the ﬁrst year
after treatment initiation was similarly high in both groups (38% in
the MDex cohort and 34% in the BMDex group). There was no
signiﬁcant difference in overall survival (Figure 1a) and in time to
second-line therapy or death (Figure 1b) between the two cohorts.
However, in a 6-month landmark analysis excluding patients who
died early, subjects treated with BMDex had a signiﬁcant survival
advantage (Figure 2).
In the overall study population, New York Heart Association
class III or IV heart failure and a NT-proBNP concentration
48500 ng/l were associated with very poor survival (median 9
vs 61 months, and 11 vs 64 months, respectively, Po0.001). The
patients with both risk factors had a median survival of only
3 months. The rate of cardiac response, however, was no different
between patients with none (11 responders out of 62 patients
evaluable for cardiac response, 18%) and one and/or two risk
factors (11 responders out of 86 patients, 13%, P= 0.403). The
addition of bortezomib did not improve the outcome of patients
with severe heart failure (New York Heart Association class 4III)
and/or with NT-proBNP 48500 ng/l. However, subjects without
these risk factors who received bortezomib survived signiﬁcantly
longer than those receiving MDex alone (Figure 3). Even in this
group of patients, there was no signiﬁcant survival advantage for
BMDex, if full-dose dexamethasone could be used (15 patients in
each group, 98 vs 86% surviving 2 years, with MDex and BMDex,
respectively, P= 0.965). Also in the 6-month survival analysis, there
was no signiﬁcant beneﬁt for the BMDex cohort in patients who
received full-dose dexamethasone (median survival not reached in
both groups, with 89% of patients surviving 2 years in the MDex
group and 83% in the BMDex group, P= 0.892). As expected,
Table 2. Hematologic response to treatment (by intent-to-treat)
Patient population Response category MDex N (%) BMDex N (%) P
Overall population (87 patients in each cohort) Overall hematologic response 44 (51) 60 (69) 0.013
CR 17 (19) 37 (42) 0.002
VGPR 5 (6) 11 (13) 0.143
PR 22 (26) 12 (14) 0.056
Patients treated with full-dose dexamethasonea
(23 patients in each cohort)
Overall hematologic response 16 (70) 17 (74) 0.743
CR 7 (30) 11 (48) 0.227
VGPR 2 (9) 4 (17) 0.381
PR 7 (30) 2 (9) 0.135
Abbreviations: BMDex, bortezomib, melphalan and dexamethasone; CR, complete response; MDex, melphalan plus dexamethasone; PR, partial response;
VGPR, very good partial response. aDexamethasone 40mg on days 1–4.
Table 1. Patients’ characteristics
Variables MDex (87 patients)
N (%) or median (IQR)
BMDex (87 patients)
N (%) or median (IQR)
P
Age, years 69 (62–74) Matched
Heart involvement 74 (85) Matched
Renal involvement 55 (63) Matched
Cardiac stage I/II/III 13 (15)/39 (45)/35 (40) Matched
NT-proBNP 48500 ng/l 19 (22) Matched
Systolic blood pressure o100mmHg 3 (3) Matched
Full-dose dexamethasone 23 (26) Matched
eGFR o30ml/min 6 (7) Matched
dFLC 4180mg/l 44 (51) Matched
NYHA class III or IV 39 (45) 37 (42) 0.760
NT-proBNP, ng/l 3328 (998–8007) 2753 (1062–6706) 0.558
cTnI, ng/ml 0.064 (0.020–0.187) 0.079 (0.021–0.162) 0.877
Proteinuria, g/24 h 0.9 (0.3–4.1) 1.3 (0.64–6.3) 0.386
eGFR, ml/min per 1.73m2 69 (50–86) 71 (53–95) 0.288
Liver involvement 10 (11) 9 (10) 0.808
Peripheral nervous system involvement 17 (19) 5 (6) 0.006
Number of organs involved 2 (1–3) 2 (1–2) 0.202
dFLC, mg/l 185 (85–516) 199 (108–570) 0.734
Bone marrow plasma cell, % 12 (7–20) 13 (10–20) 0.216
Number of treatment cycles 3 (3–6) 4 (2–6) 0.428
Treated in 2005–2006 18 (21) 0 (0) —
Treated in 2007–2009 41 (47) 19 (22) o0.001
Treated in 2010–2012 28 (32) 68 (78) o0.001
Abbreviations: BMDex, bortezomib, melphalan and dexamethasone; cTnI, cardiac troponin I; dFLC, difference between involved (amyloidogenic) and
uninvolved circulating free light chain; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; MDex, melphalan plus dexamethasone; NT-proBNP,
amino-terminal pro-natriuretic peptide type-B; NYHA, New York Heart Association.
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survival was not affected by treatment type within each response
category (that is, CR, very good partial response and partial
response). The classical and revised Mayo Clinic staging system
failed to identify a group of patients in whom treatment type was
associated with a signiﬁcant difference in survival.
In the MDex cohort, 35 patients received second-line therapy
that was bortezomib plus dexamethasone in 18 cases, thalidomide
based in 11 subjects and lenalidomide based in 6 patients.
Hematologic response rate was 56% in bortezomib-treated
patients. Three patients responded to lenalidomide, and one to
thalidomide. In the BMDex cohort, 18 patients received rescue
therapy that was lenalidomide based in 8 cases, thalidomide
based in 5 cases and pomalidomide and dexamethasone in 5. Two
patients responded to thalidomide, 3 to pomalidomide and 3 to
lenalidomide. Interestingly, in the 6-month landmark analysis, the
use of bortezomib upfront was still associated with a longer
survival compared with sequential use of MDex and bortezomib
(median 31 months vs not reached, P= 0.034).
DISCUSSION
Light chain amyloidosis is a very heterogeneous disease and the
outcome is strictly dependent on the severity of organ damage,
Figure 1. Survival according to treatment type. (a) Overall survival,
median 30 months (95% conﬁdence interval: 14–51 months) in
the MDex cohort vs not reached (95% conﬁdence interval:
19 months—not reached) in the BMDex cohort (P= 0.418). (b) Time
to second-line therapy or death, median 22 months (95%
conﬁdence interval: 12–36 months) in the MDex cohort vs 39 months
(95% conﬁdence interval: 15–41 months) in the BMDex cohort
(P= 0.310). BMDex, 87 cases; MDex, 87 matched controls.
Figure 2. Six-month landmark analysis of survival according to
treatment type. Median 47 months (95% conﬁdence interval:
30–61 months) vs not reached (95% conﬁdence interval: 41
months—not reached), P= 0.031. BMDex, 63 patients; MDex, 69
patients.
Figure 3. Survival according to NYHA class, NT-proBNP concentra-
tion and treatment type. Continuous lines indicate patients treated
with MDex, dotted lines indicate subjects treated with BMDex.
(a) NYHA class o III and NT-proBNP ⩽ 8500 ng/l treated with BMDex,
46 patients, median survival not reached (lower 95% conﬁdence
interval not reached; 86% surviving 2 years, 95% conﬁdence interval
75–98%), P= 0.014 compared with group b. (b) NYHA class o III and
NT-proBNP ⩽ 8500 ng/l treated with MDex, 42 patients, median
survival 61 months (95% conﬁdence interval 23 months—not
reached). (c) NYHA class 4III or NT-proBNP 48500 ng/l treated
with BMDex, 26 patients, median survival 15 months (95%
conﬁdence interval 8–41 months), P=0.783 compared with group d.
(d) NYHA class 4III or NT-proBNP 48500 ng/l treated with MDex,
33 patients, median survival 20 months (95% conﬁdence interval
7–46 months). (e) NYHA class 4III and NT-proBNP 48500 ng/l
treated with BMDex, 15 patients, median survival 3 months (95%
conﬁdence interval 2–6 months), P= 0.269 compared with group f.
(f ) NYHA class4III and NT-proBNP48500 ng/l treated with BMDex,
12 patients, median survival 4 months (95% conﬁdence interval
3–6 months). There was no signiﬁcant difference in survival between
patients treated with MDex and BMDex among subjects with NYHA
class 4II or NT-proBNP 48500 ng/l.
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particularly cardiac dysfunction, not only directly affecting
patients’ survival but also limiting the possibility of employing
effective regimens.9,45 In the present study, we analyzed two
cohorts of patients with AL amyloidosis matched for all the most
important disease-related prognostic factors. All the 87 patients
diagnosed at our center and treated with BMDex frontline during
the study period were included. The availability of a large
population of patients treated with MDex (335 subjects) allowed
for accurate matching. However, MDex patients were generally
treated earlier than BMDex subjects, and had less options for
rescue treatment.
Importantly, the study population was characterized by a
remarkably elevated proportion of high-risk patients. Only one
fourth of the subjects were deemed ﬁt enough to receive full-dose
dexamethasone, which is independently associated with higher
response rates and prolonged survival.26 Indeed, in our study,
BMDex granted a lower rate of hematologic response compared
with that reported by Gasparetto et al.46 in the ﬁrst prospective
phase II trial of BMDex in AL amyloidosis (94%, with 56% CRs in 16
patients). This might be explained by the high proportion of
patients with advanced disease receiving attenuated dexametha-
sone in our unselected series.
Although BMDex granted a signiﬁcantly higher rate of CRs (42
vs 19%), this was not associated with improved overall survival,
nor with longer time to second-line treatment or death in the
overall population. With more than one third of patients dying in
the ﬁrst year after diagnosis in both cohorts, the presence of
advanced, irreversible, cardiac dysfunction was the main determi-
nant of survival. The addition of bortezomib could not overcome
the poor prognosis of patients with severe heart involvement,
identiﬁed by New York Heart Association class III and/or IV heart
failure and/or NT-proBNP 48500 ng/l. This high concentration of
NT-proBNP has been shown a marker of very poor outcome in AL
amyloidosis in a large European study.3 It is likely that the
unsatisfactory cardiac response rate (13% with MDex and 16%
with BMDex) is responsible for the dismal outcome of patients
with advanced cardiac disease who can survive only if their
cardiac damage improves. However, when subjects with severe
heart involvement were excluded, a survival beneﬁt associated
with the addition of bortezomib appeared.
We observed that when full-dose dexamethasone was used, there
was no difference in response rate, quality of response and survival
between BMDex and MDex patients. However, this subgroup analysis
was limited by the small number of patients and by the fact that
these subjects were selected for less severe organ involvement,
requiring a longer follow-up for survival differences to emerge.
Overall, our study showed that the outcome of patients with
advanced cardiac dysfunction remains dismal even with BMDex,
and the attempt to exploit the synergy of low-dose three-drug
combination does not seem the conclusive answer for patients
with advanced cardiac AL amyloidosis. Innovative strategies are
urgently needed for these unfortunate patients. Our data suggest
that ‘intermediate-risk’ patients, who do not have advanced heart
failure at diagnosis, but still are not ﬁt enough to receive full-dose
dexamethasone, are those who are more likely to take advantage
from the combination of BMDex. The small number of low-risk
patients included in the present study and the relatively short
follow-up prevent us to draw conclusions on the utility of adding
bortezomib to MDex in these subjects. The ongoing phase III
randomized and stratiﬁed clinical trial comparing full-dose BMDex
and MDex (NCT01277016), will clarify the ideal setting for
employing the combination of bortezomib, melphalan and
dexamethasone in AL amyloidosis.
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